NCT05024149

Brief Summary

Three groups of subjects will be included: 20 subjects in the healthy control group, 20 subjects in the MDD electroacupuncture (EA) intervention group, and 20 subjects in the MDD waiting-list group (participants will receive no treatment within 4 weeks). The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera. The average facial temperature and acupoints temperature will be analyzed and compared within 3 groups. In addition, the correlation between facial infrared radiation characteristics of MDD patients and emotional changes will be explored. Besides, the relative specificity of the two meridians will be investigated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable major-depressive-disorder

Timeline
Completed

Started Jul 2021

Typical duration for not_applicable major-depressive-disorder

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 12, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

August 27, 2021

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

January 31, 2023

Status Verified

January 1, 2023

Enrollment Period

2.5 years

First QC Date

August 12, 2021

Last Update Submit

January 27, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Average facial temperature

    Take the average facial temperature of 10 infrared images as the observation index, observe the change rule of the average temperature of MDD patient by comparing with healthy people.

    Change from Baseline average facial temperature at 4 weeks

Secondary Outcomes (2)

  • Infrared thermal images

    Change from Baseline average facial temperature at 4 weeks

  • Hamilton depression scale (HAMD)

    HAMD will be performed in the first week, the second week and the fourth week to evaluate the severity of the disease and the treatment effect.

Study Arms (3)

Healthy group

EXPERIMENTAL

Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.

Other: infrared thermography (IRT)

MDD electroacupuncture intervention group

EXPERIMENTAL
Other: infrared thermography (IRT)

MDD waiting-list group

EXPERIMENTAL

In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.

Other: infrared thermography (IRT)

Interventions

The temperature and infrared thermography (IRT) images of the facial acupoints of three groups will be recorded by an infrared thermal-imaging camera.

Healthy groupMDD electroacupuncture intervention groupMDD waiting-list group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subjects should provide a physical examination report within the last year, which could confirm they had not major systemic diseases, such as cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;
  • ≤ age ≤ 60 years, both gender;
  • Subjects have clear consciousness and could communicate with others normally;
  • Subjects could understand the full study protocol and written informed consent is provided by themselves. Note: Subjects who meet the above four items will be included.
  • Meeting the above diagnostic criteria for MDD;
  • PHQ-9 score of 5 to 14, HAMD score of 21 to 35, and a diagnosis of mild or moderate depression by a specialist; (3)18 ≤ age ≤ 60 years, both gender;
  • (4) Patients have clear consciousness and could communicate with others normally; (5) Patients could understand the full study protocol and written informed consent is provided by themselves; (6) Those who did not use other therapies other than the basic treatment and this experimental therapy. The basic treatment refers to basic antidepressant medications under the supervision of a specialist. The basic antidepressant medications are Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic antidepressants, Monoamine Oxidase Inhibitors. Note: Subjects who meet the above six items will be included.

You may not qualify if:

  • Subjects suffering from mental illness, severe depression, alcohol dependence or a history of drug abuse;
  • Subjects in pregnancy, lactation or menstrual period;
  • Subjects have a fever;
  • Subjects have visible skin damage or scars in the face;
  • Subjects participating in other trials. Note: Subjects who meet any of the above will be excluded.
  • Patients with bipolar disorder;
  • Patients with schizophrenia or other mental disorders;
  • Patients with severe medical diseases, tumors or diseases of the central nervous system;
  • Patients suffering from severe depressive episode with psychotic symptoms;
  • Suicidal patients;
  • Patients with seasonal depression;
  • Patients with organic depression;
  • Patients with alcohol or drug addicts;
  • Patients using other therapies;
  • Patients in pregnancy or lactation;
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xiaoyu Li

Hangzhou, Zhejiang, 310053, China

Location

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Doctor

Study Record Dates

First Submitted

August 12, 2021

First Posted

August 27, 2021

Study Start

July 1, 2021

Primary Completion

December 30, 2023

Study Completion

December 30, 2024

Last Updated

January 31, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, ICF, CSR

Locations